Pradžia › Kartotinė mieloma › Florida › Miami
Kartotinė mieloma klinikiniai tyrimai Miami, FL
Vienas tyrimas dėl Kartotinė mieloma ieško dalyvių vietoje Miami arba jos apylinkėse. Atidarykite jį, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Renkami dalyviai1/2 fazė
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Renkami dalyviai2 fazė
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- ir dar 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Renkami dalyviai2 fazė
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Renkami dalyviai3 fazė
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Renkami dalyviai3 fazė
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- ir dar 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Renkami dalyviai3 fazė
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Renkami dalyviai2 fazė
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Renkami dalyviai1/2 fazė
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Renkami dalyviai1 fazė
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Renkami dalyviai4 fazė
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Renkami dalyviai
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Renkami dalyviaiStebimasis tyrimas
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Renkami dalyviai1/2 fazė
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Renkami dalyviai2 fazė
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Renkami dalyviai2 fazė
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Kartotinė mieloma tyrimai kituose miestuose
- New York City, NY60 tyrimai
- Boston, MA42 tyrimai
- Atlanta, GA41 tyrimas
- Houston, TX38 tyrimai
- Durham, NC37 tyrimai
- Nashville, TN32 tyrimai
- Denver, CO27 tyrimai
- Rochester, MN24 tyrimai
- St. Louis, MO24 tyrimai
- Columbus, OH24 tyrimai
- Baldwin Park, CA23 tyrimai
- Chicago, IL22 tyrimai
Kiti tyrimai Miami
- Krūties vėžys42 tyrimai
- Vėžys (visų tipų)36 tyrimai
- Nedidelinių ląstelių plaučių vėžys31 tyrimas
- Prostatos vėžys27 tyrimai
- Nutukimas27 tyrimai
- Ūmi mieloidinė leukemija24 tyrimai
- Metastatinis vėžys24 tyrimai
- Kiaušidžių vėžys23 tyrimai
- Antsvoris23 tyrimai
- Opinis kolitas21 tyrimas
- Alzheimerio liga20 tyrimai
- Plaučių vėžys20 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.